Trending...
- HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
- New Luxury Single Family Homes From $976,990 in Manalapan
- K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
More on Nyenta.com
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
More on Nyenta.com
- Raja Limousine Expands Premium Airport Transportation Across New York
- Learn Window Tint in New York This July!
- SULAAH Expands Lost Files With "THE BEAT" Lyric Video and AI-Assisted Sound Series
- STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
- Nyasia Chane'l Celebrates 5 Years of Clubhouse No. 7 With Deluxe Edition
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
- Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
- Love All: Liberty Open 2026 Serves Pride with USTA Partnership
- Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
- Team USA Paralympic Medalist Mohamed Lahna Starts Historic Triathlon Across America on June 13
- Fullyfocusedmgnt presents breakout to summer
- TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
- Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
- Thrive Wellness & Aesthetics Named Double Winner in Westchester Magazine's Best of Westchester
- Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Turn Old Devices Into Income: Wnode Launches the New Compute Economy
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- the Boardroom Experience Comes to ACI's WILS Boston this Summer!
- NYC Estimating Expands Professional Construction Estimating Services Across New York
- Michelob ULTRA Enlists FANZO and Men In Blazers to Launch Out-of-Home Campaign for FIFA World Cup
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- Summer Sip Returns July 19 with 10 Hudson Valley Wineries, Live Music, Food and New Grand Reserve Experience
- TimeLyss MedSpa Hosts Summer Glow Social on Manhattan's Upper West Side